Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Bioorg Med Chem. 2017 Jun 27;25(16):4464–4474. doi: 10.1016/j.bmc.2017.06.035

Figure 7.

Figure 7

Treatment of SKOV-3 human derived ovarian cancer cells with compound 4, 6, and 7 at 10 μM concentration showed enhanced cell growth at 96, and 120 hour time points with 24 hour (constant) drug treatment (Left Panels), and reduced growth at the same time points when the “low-dose naltrexone” regimen of pulsed therapy is used (Right Panels). Here the “low-dose” therapy is achieved by pulsing drug on for 6 hours every other day.